- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04750798
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
An Observational Post-marketing Study for Evaluation of Ongoing Safety and Effectiveness of Catheter Mapping and Ablation Using Commercially Approved BWI Medical Devices for the Treatment of Patients With Cardiac Arrhythmias
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nathalie Macours
- Phone Number: +32 479 97 05 05
- Email: nmacours1@its.jnj.com
Study Locations
-
-
-
Linz, Austria, 4020
- Recruiting
- Ordensklinikum Linz GmbH
-
-
-
-
-
Aalst, Belgium, 9300
- Recruiting
- OLV Aalst
-
Brugge, Belgium, 8000
- Recruiting
- AZ Sint-Jan Brugge
-
Edegem, Belgium, 2650
- Recruiting
- UZ Antwerp
-
Hasselt, Belgium, 3500
- Recruiting
- Jessa Hospital
-
Jette, Belgium, 1090
- Recruiting
- UZ Brussels
-
La Louvière, Belgium, 7100
- Recruiting
- ASBL CHU HELORA Hôpital de La Louvière site Jolimont
-
-
-
-
-
Talence, France, 33404
- Recruiting
- Centre Hospitalier Universitaire de Bordeaux
-
-
-
-
-
Bad Neustadt an der Saale, Germany, 97616
- Recruiting
- Rhön-Klinikum Campus Bad Neustadt
-
Frankfurt, Germany, 60431
- Recruiting
- Cardioangiologisches Centrum Bethanien (CCB)
-
Munich, Germany, 80636
- Recruiting
- German Heart Centre Munich
-
-
-
-
-
Dublin, Ireland, D07 WKW8
- Recruiting
- Mater Private Heart and Vascular Centre
-
-
-
-
-
Jerusalem, Israel, 9103102
- Recruiting
- Shaare Zedek Medical Center
-
Tel Aviv, Israel, 6423906
- Recruiting
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Acquaviva delle Fonti, Italy, 70021
- Recruiting
- Ospedale Generale Regionale "F. Miulli"
-
-
-
-
-
Leicester, United Kingdom, LE3 9QP
- Recruiting
- Glenfield Hospital
-
London, United Kingdom, SW17 0QT
- Recruiting
- St George's Hospital
-
London, United Kingdom, EC1A 7BE
- Recruiting
- St. Bartholomew's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria
- Diagnosed with paroxysmal or persistent Atrial Fibrillation (AF) or supraventricular tachycardia (SVT) or ventricular tachycardia (VT) and scheduled to undergo an ablation procedure for management of their arrhythmia with a per-protocol defined BW therapeutic catheter
- Able and willing to comply with all pre, post and follow-up testing and requirements as per hospital standard of care
- Signed patient informed consent form (ICF) as applicable per local regulation
Exclusion criteria:
- Currently participating in an interventional (drug, device, biologic) clinical trial
- Life expectancy of less than 12-months
- Presenting any contraindication for the use of BWI commercially approved medical devices, as indicated in the respective user manuals
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants Diagnosed with Cardiac Arrhythmias
Patients diagnosed with cardiac arrhythmias who are scheduled to undergo an ablation procedure in routine clinical practice for management of their arrhythmia with a BWI therapeutic catheter/Varipulse Catheter will be observed.
|
Participants will be treated with commercially approved BWI medical devices following routine clinical practice.
No specific intervention will be observed for this study.
Participants treated with Varipulse Catheter in the main study will be part of the VARIPURE sub-study.
No specific intervention will be observed for this study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AF: Number of Participants with Isolation of all Targeted Pulmonary Veins
Time Frame: Up to 7 Days
|
Number of Participants with isolation (entrance block confirmation) of all targeted pulmonary veins will be reported.
|
Up to 7 Days
|
SVT (Sinus Nodal Re-entrant Tachycardia, Focal AT, Multifocal AT, AVNRT, Non Re-entrant Junctional Tachycardias): Number of Participants with Non-inducibility of the Targeted Tachycardia at end of Procedure
Time Frame: Up to 7 Days
|
Number of participants with sinus nodal re-entrant tachycardia, focal atrial tachycardia (AT) multifocal AT, atrioventricular nodal reentry tachycardia (AVNRT), non re-entrant junctional tachycardias with non-inducibility of the targeted tachycardia at end of procedure will be reported.
|
Up to 7 Days
|
SVT (MRAT): Number of Participants with Complete Bidirectional Conduction Block Across the Ablation Line
Time Frame: Up to 7 Days
|
Number of participants with Macro Re-entrant Atrial Tachycardia (MRAT) with complete bidirectional conduction block across the ablation line will be reported.
|
Up to 7 Days
|
SVT (AVRT): Number of Participants with Complete Block of Accessory Pathway
Time Frame: Up to 7 Days
|
Number of participants with atrioventricular reentry tachycardia (AVRT) with complete block of accessory pathway will be reported.
|
Up to 7 Days
|
VT (Ischemic or Non-ischemic): Number of Participants with Non-inducibility of the Targeted VT at end of Procedure
Time Frame: Up to 7 days
|
Number of participants with non-inducibility of the targeted ischemic or non-ischemic VT at end of procedure will be reported.
|
Up to 7 days
|
VT (Idiopathic): Number of Participants with Elimination of Clinically Relevant VT
Time Frame: Up to 7 days
|
Number of participants with elimination of clinically relevant idiopathic VT will be reported.
Clinically relevant: any spontaneous VT or any induced VT.
|
Up to 7 days
|
VT (Idiopathic): Number of Participants with Elimination of Clinically Relevant Premature Ventricular Contraction (PVCs)
Time Frame: Up to 7 days
|
Number of participants with elimination of clinically relevant idiopathic PVCs will be reported.
Clinically relevant: any spontaneous PVC or any induced PVC; prior to treatment, PVCs would be deemed clinically relevant if they are present greater than (>) 20 percent (%) of daily heartbeat.
|
Up to 7 days
|
Number of Participants with Primary Adverse Events (PAEs) Related to Device in Scope and/or Study Procedure Within 7 Days of the Initial Study Procedure
Time Frame: Up to 7 Days
|
PAEs in participants with Atrial Fibrillation (AF) and for SupraVentricular Tachycardia (SVT) includes device or procedure related death, atrio-esophageal fistula/ esophageal perforation , severe pulmonary vein stenosis, cardiac tamponade/perforation, thromboembolism, pericarditis, stroke/cerebrovascular accident, transient ischemic attack, phrenic nerve paralysis (permanent), myocardial infarction, major vascular access complication/bleeding, heart block; PAEs in participants with Ventricular Tachycardia (VT) includes device or procedure related death, cardiac tamponade/perforation, thromboembolism, pericarditis, stroke/cerebrovascular accident, transient ischemic attack, phrenic nerve paralysis (permanent), myocardial infarction, major vascular access complication/bleeding, heart block, aggravation or new onset heart failure, coronary artery injury, aortic dissection and valve injury.
|
Up to 7 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Device and/or Procedure-Related Serious Adverse Events (Serious Adverse Device Effects [SADEs])
Time Frame: Up to 365 Days
|
Number of participants with device and/or procedure-related Serious Adverse Events (SADEs) within 7 days (early-onset), >7-30 days (peri-procedural) and >30 days (late onset) following the initial study procedure will be reported.
|
Up to 365 Days
|
Number of Participants with Device and/or Procedure-Related Non-Serious Adverse Events (Non-Serious Adverse Device Effects [ADEs])
Time Frame: Up to 365 Days
|
Number of participants with device and/or procedure-related non-serious adverse events (Non-serious ADEs) within 7 days (early-onset), >7-30 days (peri-procedural) and >30 days (Late Onset) following the initial study procedure will be reported.
|
Up to 365 Days
|
AF: Number of Participants with Acute Reconnection Among all Targeted Pulmonary Veins (PVs)
Time Frame: Up to 7 Days
|
Number of participants with Acute reconnection among all targeted PVs will be reported.
|
Up to 7 Days
|
SVT (MRAT): Number of Participants with Non-inducibility of the Targeted Tachycardia at end of Procedure
Time Frame: Up to 7 Days
|
Number of participants with MRAT with non-inducibility of the targeted tachycardia at end of procedure will be reported.
|
Up to 7 Days
|
SVT (AVNRT): Number of Participants with Elimination or Modification of Slow Pathway Conduction
Time Frame: Up to 7 Days
|
Number of participants with AVNRT with elimination or modification of slow pathway conduction will be reported.
|
Up to 7 Days
|
VT (Ischemic or Non-ischemic): Number of Participants with Non-inducibility of any VT at end of Procedure
Time Frame: Up to 7 Days
|
Number of participants with non-inducibility of any VT (Ischemic or Non-ischemic) at end of procedure will be reported.
|
Up to 7 Days
|
VT (Ischemic or Non-ischemic): Number of Participants with Elimination of all Targeted Late Potentials and Local Abnormal Ventricular Activation (LAVAs) at end of Procedure
Time Frame: Up to 7 Days
|
Number of participants with elimination of all targeted late potentials and local abnormal ventricular activation (LAVAs) at end of procedure will be reported.
|
Up to 7 Days
|
AF: Number of Participants with Repeated Ablation
Time Frame: From Day 91 to Day 365 (post-blanking)
|
Number of participants with repeated ablation post-blanking will be reported.
|
From Day 91 to Day 365 (post-blanking)
|
AF: Number of Participants with Repeated Ablation with Pulmonary Vein (PV) Reconnection
Time Frame: From Day 91 to Day 365 (post-blanking)
|
Number of participants with repeated ablation with PV reconnection post blanking will be reported.
|
From Day 91 to Day 365 (post-blanking)
|
AF: Change in AF Burden Compared to Baseline for Participants with Implantable Arrhythmia Monitoring Device
Time Frame: Baseline, Day 91 up to Day 365
|
AF burden will be measured as the change in the percentage of time that participants will be in AF (symptomatic and asymptomatic) compared to baseline will be calculated.
The change in AF burden for the overall study population will be calculated and expressed.
|
Baseline, Day 91 up to Day 365
|
SVT: Number of Participants with Repeated Ablation
Time Frame: From Day 1 to Day 365
|
Number of participants with repeated ablation will be reported.
|
From Day 1 to Day 365
|
SVT: Change in Study Arrhythmia Burden Compared to Baseline for Participants with Implantable Arrhythmia Monitoring Device
Time Frame: From Day 1 to Day 365
|
Study arrhythmia burden will be measured as the change in the percentage of time that participants will be in study arrhythmia (symptomatic and asymptomatic) compared to baseline will be calculated.
The change in study arrhythmia for the overall study population will be calculated and expressed.
|
From Day 1 to Day 365
|
VT: Number of Participants with Repeated Ablation
Time Frame: From Day 1 to Day 365
|
Number of participants with repeated ablation will be reported.
|
From Day 1 to Day 365
|
VT: Number of Participants with All Cause and Cardiac Mortality
Time Frame: Up to Day 365
|
Number of participants with all cause and cardiac mortality will be reported.
|
Up to Day 365
|
VT: Number of Participants with Heart Failure Hospitalization
Time Frame: Up to Day 365
|
Number of participants with heart failure hospitalization will be reported.
|
Up to Day 365
|
VT (For Participants with Continuous Arrhythmia Monitoring): Number of Participants with PVC Burden
Time Frame: Up to Day 365
|
Number of participants with PVC burden for participants with continuous arrhythmia monitoring will be reported based on criterias such as % PVC beats/total beats and at least 80% reduction in PVC burden.
|
Up to Day 365
|
VT (For Participants with Implantable Arrhythmia Monitoring): Number of Participants with VT Burden
Time Frame: Up to Day 365
|
Number of participants with VT burden for participants with implantable arrhythmia monitoring will be reported based on criterias such as implantable cardioverter defibrillator (ICD) shocks (appropriate and inappropriate), appropriate antitachycardia pacing therapy (ATP), VT episodes and at least 75% reduction in VT burden.
|
Up to Day 365
|
AF: Number of Participants with Freedom From Documented (Symptomatic and Asymptomatic) AF, AT, Atrial Flutter (AFL) Episodes
Time Frame: From Day 91 to Day 365 (post-blanking)
|
Number of participants with freedom from documented (symptomatic and asymptomatic) AF, AT, AFL episodes (episodes greater than or equal to [>=] 30 seconds) post-blanking will be reported.
|
From Day 91 to Day 365 (post-blanking)
|
AF: Number of Participants with Freedom From Documented Symptomatic AF, AT, AFL Episodes
Time Frame: From Day 91 to Day 365 (post-blanking)
|
Number of participants with freedom from documented symptomatic AF, AT, AFL episodes (episodes >= 30 seconds) post-blanking will be reported.
|
From Day 91 to Day 365 (post-blanking)
|
SVT: Number of Participants with Freedom From Documented Arrhythmia of the Primary SVT
Time Frame: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of the primary SVT (episodes >=30 seconds) will be reported.
|
From Day 1 to Day 365
|
SVT: Number of Participants with Freedom From Documented Arrhythmia of new SVT, not Targeted During Index Procedure
Time Frame: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of new SVT, not targeted during index procedure will be reported.
|
From Day 1 to Day 365
|
VT: Number of Participants with Freedom From Documented Arrhythmia of the Clinically Relevant/Targeted VT
Time Frame: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of the clinically relevant /targeted VT (episodes >=30 seconds) will be reported.
|
From Day 1 to Day 365
|
VT: Number of Participants with Freedom From Documented Arrhythmia of new VT, not Targeted During Index Procedure
Time Frame: From Day 1 to Day 365
|
Number of participants with freedom from documented arrhythmia of new VT, not targeted during index procedure will be reported.
|
From Day 1 to Day 365
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VARIPURE sub-study: Assessment of Learning Curve
Time Frame: Up to Day 365
|
Learning curve will be assessed to evaluate the clinical utilization of the Varipulse Catheter in a routine-use setting.
|
Up to Day 365
|
VARIPURE sub-study: Number of Participants With Coronary Spasm During Ablation
Time Frame: Up to Day 365
|
Ablation procedures using the varipulse medical device will be performed according to the hospital standard practice.
Number of participants with coronary spasm during ablation will be reported.
|
Up to Day 365
|
VARIPURE sub-study: Number of Participants With Vagal Response During Ablation
Time Frame: Up to Day 365
|
Ablation procedures using the varipulse medical device will be performed according to the hospital standard practice.
Number of participants with vagal response during ablation will be reported.
|
Up to Day 365
|
VARIPURE sub-study: Number of Participants With Acute Kidney Failure Post Ablation
Time Frame: Up to Day 365
|
Ablation procedures using the varipulse medical device will be performed according to the hospital standard practice.
Number of participants with acute kidney failure post ablation will be reported.
|
Up to Day 365
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BWI_2019_05 (Other Identifier: Biosense Webster EMEA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel
for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrhythmias
-
Medtronic BRCCompletedAtrial Fibrillation | Risk of Cardiac ArrhythmiasNetherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
-
Ostfold University CollegeNot yet recruitingCardiac Arrest | Cardiac Arrhythmia | Cardiac Disease | Cardiac Death
-
Medical University of LodzRecruiting
-
Centro Cardiologico MonzinoMinistry of Health, ItalyRecruitingCardiac ArrhythmiaItaly
-
Ratika ParkashCardiac Arrhythmia Network of CanadaRecruiting
-
Boston Scientific CorporationRecruitingCardiac ArrythmiasUnited States, Monaco, Italy
-
EPD Solutions, A Philips CompanyPhilips HealthcareTerminatedCardiac ArrhythmiaUnited States
-
EPD Solutions, A Philips CompanyWithdrawn
-
Zoll Medical CorporationCompletedCardiac ArrhythmiaUnited States
-
Emory UniversityCompleted
Clinical Trials on BWI Medical Device
-
Karolinska University HospitalCompleted
-
Fondazione Don Carlo Gnocchi OnlusFondazione Ico FalckNot yet recruitingMultiple Sclerosis | Parkinson Disease | Post-stroke
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); University of MinnesotaCompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Reckitt Benckiser LLCCompleted
-
University Health Network, TorontoUnknown
-
University Hospital, GrenobleCommissariat A L'energie AtomiqueRecruitingHealthy Volunteers | Parkinson's Disease Patients | Para/Tetraplegic PatientsFrance
-
Prof Henry KrumHD Medical Group LtdTerminatedCardiovascular DiseasesAustralia
-
Lawson Health Research InstituteNot yet recruitingMedical Devices | Open Access | Low Cost | ElectrocardiographCanada
-
Karolinska InstitutetKällmark ClinicCompletedKeratoconjunctivitis Sicca (KCS)Sweden